BAVA:VIE
Bavarian Nordic A/S
โฌ24.84
arrow_downward
-0.16%(-0.040) 1D
4์ 29์ผ, ์ค์ 9์ 5๋ถ 14์ด GMT+2 · EUR
search
๋ชจ๋ ์ข
๋ชฉ ์ฝ๋
1D
5D
1M
6M
YTD
1Y
5Y
์ต๋
| ์ข ๋ชฉ ์ฝ๋ | ๊ฐ๊ฒฉ | ๋ณ๋ | ๋ณ๋๋ฅ (%) |
|---|
insights_autoBAVA์ ์ฃผ์ ํต๊ณ ์์ฑ ์ค...
์๊ฐ
โฌ24.84
๊ณ ๊ฐ
โฌ24.84
์ ๊ฐ
โฌ24.84
์๊ฐ์ด์ก
22.87์ต
ํ๊ท ๊ฑฐ๋๋
4.00
๊ฑฐ๋๋
0.00
52์ฃผ ์ต๊ณ ๊ฐ
โฌ32.52
52์ฃผ ์ต์ ๊ฐ
โฌ20.45
์ง์ ์
2์ฒ
๋ด์ค ๊ธฐ์ฌ
์น ์์ค ๊ธฐ๋ฐ
Yahoo Finance Singapore
·
2์ผ ์
Bavarian Nordic โ Transactions in Connection with Share Buy-Back Program
ํ๋กํ
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgรฅrd, Denmark and Thรถrishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. Wikipedia
Bavarian Nordic A/S์ ๊ดํ ์ ๋ณด
AI ์ฝํ
์ธ ์๋ ์ค๋ฅ๊ฐ ์์ ์ ์์ต๋๋ค. ์์ธํ ์์๋ณด๊ธฐ